Loading stock data…
RCUS
$25.68+0.18 (+0.71%)
Market ClosedLast close May 1
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arcus Biosciences, Inc. in the Healthcare sector is trading at $25.68. The stock is currently near its 52-week high of $28.72, remaining 38.3% above its 200-day moving average. Technical signals show neutral RSI of 63 and bullish MACD crossover, explaining why RCUS maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 63) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$25.68
Potential Upside
5%
Whystock Fair Value$26.96
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$34.00+32.4%
Range$20.00 – $47.00
Fundamentals
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney ca...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.34B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.23%
Volume
Today's trading volume
986,390
Recent News
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy?
Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcus Biosciences (RCUS) Is Up 5.2% After Lung Trial Futility Results And Gilead Option Shift
Arcus Biosciences and Gilead Sciences recently discontinued the Phase 3 STAR-121 and Phase 2 EDGE-Lung studies for domvanalimab and zimberelimab in metastatic non-small cell lung cancer after a pre-planned futility analysis, while reporting no new safety issues and confirming that zimberelimab plus chemotherapy showed overall survival in line with pembrolizumab plus chemotherapy. On the same day, Arcus disclosed that Gilead will allow its broader option rights on several early-stage Arcus...
Gilead’s Arcus Pullback and Idvynso HIV Challenge Might Change The Case For Investing In GILD
In April 2026, Arcus Biosciences said Gilead Sciences chose not to make a continuation payment, ending option rights to several early-stage Arcus programs while keeping time-limited options on select assets like AB801, AB598, AB102 and a TNF inhibitor. Around the same time, Merck’s newly approved Idvynso, a two-drug HIV regimen shown as non-inferior to Gilead’s Biktarvy, underscored rising competitive pressure in Gilead’s core HIV market just as it refines which external pipeline bets to...
Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last?
Arcus Biosciences (RCUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.